Compare TRS & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRS | REPL |
|---|---|---|
| Founded | 1986 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2004 | 2018 |
| Metric | TRS | REPL |
|---|---|---|
| Price | $38.44 | $13.04 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $45.00 | $19.50 |
| AVG Volume (30 Days) | 237.9K | ★ 2.1M |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | ★ 0.42% | N/A |
| EPS Growth | ★ 400.00 | N/A |
| EPS | ★ 21.96 | N/A |
| Revenue | ★ $645,720,000.00 | N/A |
| Revenue This Year | $4.95 | N/A |
| Revenue Next Year | $2.79 | $497.81 |
| P/E Ratio | $1.74 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $30.43 | $1.50 |
| 52 Week High | $45.43 | $16.33 |
| Indicator | TRS | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 45.93 | 46.94 |
| Support Level | $38.15 | $12.40 |
| Resistance Level | $39.91 | $13.64 |
| Average True Range (ATR) | 0.84 | 0.70 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 27.71 | 62.03 |
TriMas Corp designs, develops and manufactures a diverse set of products for the consumer products, and industrial markets . The company operates through two segments namely: The packaging segment manufactures and distributes closure and dispensing systems. The specialty product segment manufactures and distributes steel cylinders, wellhead engines, compression systems, industrial sealing, and fasteners. The packaging segment generates majority of its revenue.
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.